Retatrutide + Tirzepatide calculator
An unstandardized supplier blend of retatrutide and tirzepatide. No such combined product is approved or studied.
Also known as: Triple + dual agonist blend
FDA status — not an approved drug Not FDA-approved. Tirzepatide is approved as a single agent (Mounjaro, Zepbound), but retatrutide is investigational, and no combination of the two is approved or studied.
This draw does not fit the selected syringe.400 units exceeds the 100-unit barrel. Choose a larger syringe, use less bacteriostatic water, or split the dose.
Schedule Retatrutide + Tirzepatide → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Retatrutide + Tirzepatide is
This is an unstandardized blend sold by some research suppliers combining retatrutide (an investigational triple agonist) with tirzepatide (an approved dual GIP/GLP-1 agonist). No clinical trial has studied the combination, and no approved product contains both. Dosing and composition vary by supplier.
Research depth: 1/5 No trials of this combination; evidence is limited to the individual components. Human trials: None for the combination. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Retatrutide + Tirzepatide works
Both compounds overlap heavily — each activates GLP-1 receptors, and retatrutide additionally activates GIP and glucagon receptors while tirzepatide activates GIP. Combining two agents in the same class would be expected to amplify the same effects and side effects rather than add a new mechanism, but no data exists to characterize the result.
Retatrutide + Tirzepatide side effects
Commonly reported
- No data on the combination
- Amplified gastrointestinal effects expected from overlapping GLP-1 activity
- Nausea, vomiting, diarrhea
Serious — seek medical care
- Unstudied combination with overlapping mechanisms — additive side effects likely
- Pancreatitis, gallbladder, and dehydration risks
- Dosing and purity variability in unregulated blends
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 10 mg vial reconstituted with 10 mL of bacteriostatic water gives 1 mg/mL. A 4000 mcg dose is then 4 mL — about 400 units on a 100-unit insulin syringe, giving roughly 2 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Retatrutide + Tirzepatide dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Retatrutide + Tirzepatide run from 2400 mcg to 12000 mcg. This is an unstandardized compounded blend with no established dosing. Figures shown are reference points only and do not describe a studied regimen. Combining two incretin-class agonists has no clinical evidence base.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Retatrutide + Tirzepatide at all are decisions for a licensed clinician who knows your history.
Common questions
Is there an approved retatrutide-tirzepatide combination?
No. Tirzepatide is approved as a single agent; retatrutide is investigational. No trial has studied combining them, and blends sold by suppliers are unregulated and unstandardized.
Why would someone combine them?
There is no clinical rationale supported by evidence — both are incretin-class agonists with overlapping GLP-1 activity. Combining them is an unregulated practice without trial support.